edetic acid

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	91 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	95 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	66.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastrointestinal toxicity	405.36	69.98	87	2869	9380	90616111
Pulmonary toxicity	382.80	69.98	86	2870	11445	90614046
Neoplasm malignant	295.21	69.98	87	2869	33793	90591698
Joint injury	293.92	69.98	86	2870	32578	90592913
Hepatotoxicity	269.28	69.98	87	2869	45755	90579736
Joint stiffness	178.78	69.98	74	2882	77968	90547523
Therapy non-responder	177.10	69.98	87	2869	136617	90488874
Musculoskeletal pain	158.60	69.98	87	2869	171164	90454327
C-reactive protein abnormal	155.79	69.98	78	2878	127351	90498140
Musculoskeletal stiffness	114.81	69.98	87	2869	296445	90329046
Treatment failure	110.71	69.98	86	2870	303842	90321649
Therapeutic product effect incomplete	102.89	69.98	69	2887	193827	90431664
Infection	97.50	69.98	86	2870	362008	90263483
Pain in extremity	86.94	69.98	89	2867	450440	90175051
Joint swelling	72.00	69.98	85	2871	503215	90122276

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastrointestinal toxicity	234.38	69.70	56	3099	11092	110575052
Pulmonary toxicity	208.54	69.70	56	3099	17690	110568454
Joint injury	171.51	69.70	58	3097	39936	110546208
Neoplasm malignant	167.72	69.70	56	3099	37087	110549057
Hepatotoxicity	138.51	69.70	56	3099	63344	110522800
Central nervous system mass	135.21	69.70	23	3132	811	110585333
Wall motion score index abnormal	135.01	69.70	23	3132	818	110585326
Airway remodelling	132.41	69.70	23	3132	919	110585225
Joint stiffness	128.58	69.70	54	3101	67189	110518955
Atopy	127.75	69.70	23	3132	1131	110585013
Cardiac septal defect	118.13	69.70	21	3134	960	110585184
Eosinophilic myocarditis	114.17	69.70	23	3132	2062	110584082
Microangiopathy	106.04	69.70	23	3132	2949	110583195
Therapy non-responder	90.26	69.70	56	3099	157251	110428893
Eosinophil count decreased	89.90	69.70	23	3132	5995	110580149
Nodule	89.44	69.70	34	3121	32597	110553547
Eosinophilic pneumonia	85.72	69.70	23	3132	7204	110578940
Blood immunoglobulin E increased	84.93	69.70	23	3132	7459	110578685
Musculoskeletal pain	82.50	69.70	56	3099	182967	110403177
Respiratory symptom	77.31	69.70	25	3130	14920	110571224
C-reactive protein abnormal	76.46	69.70	47	3108	129648	110456496
Ventricular hypokinesia	75.73	69.70	23	3132	11191	110574953
Eosinophilic granulomatosis with polyangiitis	72.52	69.70	22	3133	10664	110575480
Nasal polyps	72.04	69.70	23	3132	13177	110572967

Source	Code	Description
FDA PE	N0000008556	Decreased Coagulation Factor Activity
FDA MoA	N0000175089	Calcium Chelating Activity
MeSH PA	D000925	Anticoagulants
MeSH PA	D002614	Chelating Agents
MeSH PA	D005503	Food Additives
MeSH PA	D006401	Hematologic Agents
MeSH PA	D064449	Sequestering Agents
MeSH PA	D065096	Calcium Chelating Agents
FDA MoA	N0000175962	Lead Chelating Activity
FDA EPC	N0000175963	Lead Chelator
FDA EPC	N0000175980	Anti-coagulant
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:66981	ophthalmology drug

Disease	Relation	SNOMED_ID	DOID
Digitalis toxicity by EKG	indication	6412007
Hypercalcemia	indication	66931009	DOID:12678
Accidental poisoning by lead and its compounds and fumes	indication	216777009
Cerebral edema	contraindication	2032001
Anuria	contraindication	2472002	DOID:2983
Hypocalcemia	contraindication	5291005
Dehydration	contraindication	34095006
Hypokalemia	contraindication	43339004
Chronic heart failure	contraindication	48447003
Acute nephropathy	contraindication	58574008
Oliguria	contraindication	83128009
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Inflammatory disease of liver	contraindication	128241005
Pulmonary tuberculosis	contraindication	154283005	DOID:2957
Disease of liver	contraindication	235856003	DOID:409
Lesion of brain	contraindication	301766008

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

edetic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.96	acidic
pKa2	1.56	acidic
pKa3	2.15	acidic
pKa4	2.75	acidic
pKa5	10.12	Basic
pKa6	6.12	Basic

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	IC50	4.85	CHEMBL
Ceramide glucosyltransferase	Enzyme	Q16739	CEGT_HUMAN			WOMBAT-PK
Amyloid beta A4 protein	Membrane other	P05067	A4_HUMAN	IC50	5.11	CHEMBL
Eyes absent homolog 2	Enzyme	O00167	EYA2_HUMAN	IC50	4.19	CHEMBL
Beta-lactamase	Enzyme		Q79MP6_PSEAI	IC50	4.55	CHEMBL
Beta-lactamase VIM-1; Class B carbapenemase VIM-1; Metallo-beta-lactamase; Metallo-beta-lactamase VIM-1; Metallobeta-lactamase; VIM-1; VIM-1 metallo-beta lactamase; VIM-1 metallo-beta-lactamase; VIM-1	Enzyme		Q9XAY4_PSEAI	IC50	5.03	CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Enzyme		J3SE37_CROAD	IC50	4.13	CHEMBL
Beta-lactamase NDM-1	Enzyme		BLAN1_KLEPN	IC50	6.40	CHEMBL

ID	Source
4031052	VUID
N0000183560	NUI
D00052	KEGG_DRUG
6381-92-6	SECONDARY_CAS_RN
4017473	VANDF
4017479	VANDF
4017590	VANDF
4018923	VANDF
4020659	VANDF
4031052	VANDF
C0013618	UMLSCUI
CHEBI:4735	CHEBI
CHEMBL858	ChEMBL_ID
CHEMBL3989507	ChEMBL_ID
DB00974	DRUGBANK_ID
CHEMBL3989522	ChEMBL_ID
D004492	MESH_DESCRIPTOR_UI
6049	PUBCHEM_CID
534	INN_ID
6766-87-6	SECONDARY_CAS_RN
9G34HU7RV0	UNII
1903	RXNORM
23	MMSL
30988	MMSL
3413	MMSL
4651	MMSL
4652	MMSL
728	MMSL
NOCODE	MMSL
d00742	MMSL
d01403	MMSL
001090	NDDF
001091	NDDF
002560	NDDF
003785	NDDF
387418006	SNOMEDCT_US
387428002	SNOMEDCT_US
69519002	SNOMEDCT_US
EDT	PDB_CHEM_ID

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Edetate Calcium Disodium	Human Prescription Drug Label	1	64980-588	INJECTION	200 mg	INTRAMUSCULAR	ANDA	23 sections
YIGANERJING SuifurSoap	HUMAN OTC DRUG LABEL	3	71939-003	SOAP	0.07 g	TOPICAL	unapproved drug other	7 sections
MIIN FOOT	HUMAN OTC DRUG LABEL	4	72988-0014	LIQUID	0.05 g	TOPICAL	OTC monograph not final	7 sections
Miracle FootCream Lavender	HUMAN OTC DRUG LABEL	4	82145-0005	CREAM	0.05 g	TOPICAL	unapproved drug other	7 sections
Miracle FootCream Lemon	HUMAN OTC DRUG LABEL	4	82145-0006	CREAM	0.05 g	TOPICAL	unapproved drug other	7 sections
Anubis Barcelona	HUMAN OTC DRUG LABEL	12	83021-495	CONCENTRATE	0 g	TOPICAL	OTC monograph final	9 sections
Anubis Barcelona	HUMAN OTC DRUG LABEL	13	83021-839	CONCENTRATE	0 g	TOPICAL	OTC monograph final	9 sections